| Literature DB >> 22536871 |
Richard C McEachin1, Keerthi S Sannareddy, James D Cavalcoli, Alla Karnovsky, Jacqueline M Vink, Maureen A Sartor.
Abstract
BACKGROUND: Predisposition to complex diseases is explained in part by genetic variation, and complex diseases are frequently comorbid, consistent with pleiotropic genetic variation influencing comorbidity. Genome Wide Association (GWA) studies typically assess association between SNPs and a single-disease phenotype. Fisher meta-analysis combines evidence of association from single-disease GWA studies, assuming that each study is an independent test of the same hypothesis. The Rank Product (RP) method overcomes limitations posed by Fisher assumptions, though RP was not designed for GWA data.Entities:
Mesh:
Year: 2012 PMID: 22536871 PMCID: PMC3375629 DOI: 10.1186/1471-2105-13-S2-S8
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Comparison of modRP results to control studies
| Lind, et al., Published Results | Our Results, Corrected Threshold: 6.54E-08 | ||||||
|---|---|---|---|---|---|---|---|
| rs7530302 | rs7530302 | 2.33E-07 | |||||
| rs1784300 | rs1784300 | ||||||
| rs12882384 | rs12882384 | 2.16E-07 | 5.51E-07 | 1.08E-07 | |||
| rs2247219 | 6.23E-06 | rs2247219 | 2.22E-05 | 2.02E-05 | 1.52E-05 | 1.41E-05 | |
| rs6705087 | 4.80E-06 | rs6705087 | 1.16E-05 | 1.12E-05 | 4.02E-06 | 5.64E-06 | |
| N/A | rs1784300 | 1.05E-07 | 1.27E-07 | ||||
| rs1938584 | 3.00E-03 | rs1476880 | 1.36E-04 | 1.41E-04 | 1.32E-04 | 1.41E-04 | |
| rs1516003 | 9.00E-04 | rs1333962 | 1.80E-02 | 1.16E-05 | 1.01E-05 | 1.15E-05 | |
| rs769592 | 2.00E-03 | rs2194 | 4.20E-02 | 3.48E-04 | 3.47E-04 | 3.47E-04 | |
| rs1937443 | 4.00E-03 | rs6505380 | 1.30E-05 | 1.37E-04 | 1.48E-04 | 1.37E-04 | |
Comparison of Lind and Yu results with results from our four tested methods. Tests that satisfied the Bonferroni correction threshold are in bold.
Results from modRP analysis of cocaine (C), opium (O), nicotine (N), and alcohol (A) dependence comorbidities in Combined, EA, and AA populations.
| COMBINED (EA & AA) Population | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CO | rs1476880* | 3.30E-05 | |||||||
| rs1476880 | 1.55E-05 | CON | CN | ||||||
| rs1426165 | 2.68E-03 | CNA | rs1426165 | 6.87E-04 | CN | rs1426165 | 2.97E-04 | ADAMTSL3 | |
| rs1169791* | 1.23E-05 | CNA | rs1925156* | 1.20E-05 | CA | rs1938584* | 3.07E-05 | ||
| COA | rs1938584* | 3.35E-05 | ON | rs1860148* | 5.61E-05 | ||||
| ONA | rs1385513* | 1.07E-04 | OA | rs726427* | 3.66E-04 | ||||
| NA | rs2169325* | 1.57E-04 | |||||||
| CO | rs1476880 | 3.32E-05 | |||||||
| rs1476880 | 1.59E-05 | CON | CN | ||||||
| rs1426165 | 2.67E-03 | CNA | rs1426165 | 6.87E-04 | CN | rs1426165 | 2.97E-04 | ADAMTSL3 | |
| rs1169791* | 1.26E-05 | CNA | rs1925156* | 1.20E-05 | CA | rs1938584* | 3.06E-05 | ||
| COA | rs1938584* | 3.33E-05 | ON | rs1860148* | 5.61E-05 | ||||
| ONA | rs1385513* | 1.07E-04 | OA | rs726427* | 3.66E-04 | ||||
| NA | rs2169325* | 1.57E-04 | |||||||
| CON | rs726344* | 2.70E-05 | CO | rs1015343* | 9.50E-05 | ||||
| rs1476880 | 2.46E-04 | CON | rs1476880 | 4.47E-05 | CN | rs1476880 | 2.01E-05 | SOD3 | |
| rs1426165 | 7.44E-05 | CNA | CN | ||||||
| COA | rs910633* | 8.32E-05 | CA | rs763869* | 4.54E-05 | ||||
| ON | rs897119* | 1.05E-04 | |||||||
| rs795734* | 5.03E-05 | ONA | rs795734* | 9.12E-06 | OA | rs795734 | 7.06E-05 | ||
| NA | rs795734 | 1.07E-04 | |||||||
In each population, the 4-way (Four), 3-way (Three), and 2-way (Two) comorbidities proceed from left to right. * Indicates the most significant result for each comorbid phenotype, in each population. For reference, complete results for rs1426165 and rs1476880 are included in each population set. Bonferroni Corrected Threshold: 8.88e-006